Publisher
Springer Berlin Heidelberg
Reference24 articles.
1. Moguilewsky M, Cotard M, Proulx L, Tournemine C and Raynaud JP: What is an antiandrogen and what is the physiological and pharmacological rationale for combined “castration + antiandrogen” therapy. In: Murphy G, Khoury S, Küss R, Chatelain C and Denis L (eds) Prostate Cancer. Part A: Research, Endocrine Treatment and Histopathology. Progress in Clinical and Biological Research. AR Liss, New York 1987 pp 315–340
2. Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Belanger A and Labrie F: The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate 1984 (5): 299–311
3. Creaven PJ, Pendyala L and Tremblay D: Pharmacokinetics and metabolism of nilutamide. Urology 1991 (37 suppl): 13–19
4. Moguilewsky M, Fiet J, Tournemine C, Raynaud JP: Pharmacology of antiandrogen, Anandron, used as an adjuvant in the treatment of prostate cancer. J Steroid Biochem 1986 (24): 139–146
5. Gaillard-Moguilewsky M: Pharmacology and antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology 1991 (37 suppl): 5–12
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hormonal therapy;Medicines for Cancer;2023